Can Open-Source insulin systems match commercial ones without meal announcements?

NCT ID NCT07758647

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether open-source automated insulin delivery (AID) systems can control blood sugar as well as commercial systems in adults with type 1 diabetes, even when meals are not announced. Participants will use both types of systems for four weeks each, with a focus on glucose levels after unannounced meals. The goal is to see if open-source systems can reduce the burden of carbohydrate counting while maintaining good glucose control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Automated insulin delivery systems (open-source and commercial)
What this could lead to
If open-source systems match commercial ones, people with type 1 diabetes may have more flexible, less burdensome options for managing blood sugar without meal announcements.
What could go wrong
This is a small crossover trial, and results may not apply to everyone. Unannounced meals could lead to high blood sugar, and the study doesn't test long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut de Recherches Cliniques de Montréal

    Montreal, Quebec, H2H 1Y8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.